RxDoctor Payments DataLook up a doctor →

Clarissa Liew, MD

Clinical Neurophysiology · Champaign, ILNPI 1942495494

Payments from drug & device makers

$9,312in general payments, 2019–2025

Across 387 payments — averaging $24.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$1K
  • AbbVie$880
  • Lilly USA, LLC$477
  • Supernus Pharmaceuticals, Inc.$453
  • Novartis$374
  • Catalyst Pharmaceuticals, Inc.$372
  • plus $6K from 48 others

What the payments were for

  • Food & beverage$9,17599%
  • Education$1371%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in Illinoisto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$159,795
Medicare patients
466
Services billed
2,708

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate22$173,579
FycompaPerampanel15$24,954
Carbidopa-LevodopaCarbidopa/Levodopa129$5,045
BelsomraSuvorexant11$4,758
Levetiracetam107$4,751
Clobazam38$4,589
Levetiracetam ErLevetiracetam24$4,506
RytaryCarbidopa/Levodopa11$4,071
Gabapentin220$3,188
Carbamazepine35$2,704
Carbamazepine ErCarbamazepine20$2,533
Memantine Hcl123$2,511
Divalproex Sodium67$2,510
Carbidopa-Levodopa ErCarbidopa/Levodopa44$1,620
Duloxetine Hcl29$1,485

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$231$173,57922 claims
Eisai Inc.Fycompa$302$24,95415 claims
Amneal Pharmaceuticals LLCRytary$182$4,07111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in Illinoison file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Champaign

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →